Theratechnologies Inc T.TH

Alternate Symbol(s): THTX

Healthcare Biotechnology

Theratechnologies Inc. is a Canada-based clinical-stage biopharmaceutical company. The Company is focused on the development and commercialization of therapies addressing unmet medical needs. It markets prescription products for people with human immunodeficiency viruses (HIV) in the United States. The Company's research pipeline focuses on specialized therapies addressing unmet medical needs in HIV, nonalcoholic steatohepatitis (NASH) and oncology. Its medicines include Trogarzo and EGRIFTA SV (tesamorelin for injection). Trogarzo (ibalizumab-uiyk) injection is a long-acting monoclonal antibody which binds to domain 2 of the CD4 T cell receptors. EGRIFTA SV (tesamorelin for injection) is approved in the United States for the reduction of excess abdominal fat in people with HIV who have lipodystrophy. Its portfolio includes Phase I clinical trial of sudocetaxel zendusortide (TH1902), a novel peptide-drug conjugate (PDC), in patients with advanced ovarian cancer.

TSX:TH - Post by User

Theratechnologies Inc > Questions

<< Previous

Bullboard Posts

Next >>

Comment by palinc2000on Jul 14, 2022 10:03am

94 Views

Post# 34823785

RE:RE:Questions

Only 2 of the 18 patients in Phase 1a remain in the trial...Do we assume that most of the 16 did not survive long enough?

qwerty22 wrote:

Seems to me they were quite defensive over oncology. I'm wondering if they are concerned that with 18 enrolled and only one clear PR that this data will be seen negatively.

For me this update is pretty good. The only real downside is it came 6 months late. It is blown away data but they hit everything they needed to hit.

I guess they are looking forward to a sizeable data set coming out of 1b and as we have said it's likely too early for that to have materialized yet.

I thought some of the colour Christain gave on the "responders" was useful. There's certainly a suggestion that there's some resistance around those patients given that in prior treatments they quickly failed on taxols. You could surmise with the PR response patient that they "beat" docetaxel.

Overall though I get the sense they are still being very cautious and conservative. Could be a while before we hear about 1b patients. Feels like a big derisk but no fanfare about that.

StableGenius97 wrote: We out here showing cancer efficacy in cancer and we out here talking about egrifta. Not the game. Egrifta. We talking about egrifta